| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99199 |
Unlisted special service, procedure or report |
658,120 |
592,109 |
$3.33M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
12,693 |
9,902 |
$920K |
| 0001A |
|
2,964 |
2,518 |
$159K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,384 |
1,007 |
$151K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
1,545 |
1,233 |
$130K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
1,490 |
1,252 |
$121K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
4,561 |
3,790 |
$119K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
8,713 |
7,145 |
$114K |
| 0002A |
|
1,858 |
1,565 |
$86K |
| 99215 |
Prolong outpt/office vis |
535 |
470 |
$83K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
720 |
608 |
$64K |
| 99502 |
|
983 |
954 |
$63K |
| T1002 |
Rn services, up to 15 minutes |
2,079 |
1,634 |
$59K |
| 99501 |
|
1,086 |
895 |
$56K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
462 |
354 |
$55K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
2,024 |
1,653 |
$55K |
| S0280 |
Medical home program, comprehensive care coordination and planning, initial plan |
861 |
758 |
$44K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
345 |
314 |
$39K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
451 |
336 |
$37K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
2,127 |
1,571 |
$32K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
3,360 |
2,800 |
$31K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
2,010 |
1,240 |
$25K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,736 |
1,391 |
$24K |
| 76801 |
|
185 |
167 |
$22K |
| 87210 |
|
5,400 |
4,172 |
$21K |
| D0145 |
Oral evaluation for a patient under three years of age |
644 |
500 |
$20K |
| 0071A |
|
285 |
219 |
$18K |
| 36415 |
Collection of venous blood by venipuncture |
5,980 |
4,701 |
$15K |
| 0004A |
|
269 |
218 |
$15K |
| 81025 |
|
1,833 |
1,499 |
$13K |
| 0072A |
|
204 |
146 |
$12K |
| 85013 |
|
4,029 |
3,269 |
$10K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
80 |
79 |
$10K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
750 |
636 |
$10K |
| 0012A |
|
161 |
151 |
$9K |
| D1206 |
Topical application of fluoride varnish |
643 |
500 |
$9K |
| 81003 |
|
2,519 |
2,075 |
$6K |
| 81001 |
|
1,822 |
1,301 |
$6K |
| 0064A |
|
115 |
100 |
$6K |
| 0011A |
|
182 |
161 |
$5K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
33 |
28 |
$5K |
| 90734 |
|
1,486 |
1,138 |
$4K |
| 82120 |
|
1,137 |
896 |
$4K |
| 90651 |
|
827 |
722 |
$4K |
| 96160 |
|
1,234 |
999 |
$4K |
| 83986 |
|
1,141 |
901 |
$4K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
3,239 |
2,572 |
$3K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
3,254 |
2,581 |
$3K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
489 |
218 |
$3K |
| 92551 |
|
1,604 |
1,290 |
$3K |
| 90474 |
|
215 |
185 |
$3K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
45 |
43 |
$3K |
| 90686 |
|
2,415 |
1,995 |
$2K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
2,914 |
2,357 |
$2K |
| 96161 |
|
508 |
399 |
$2K |
| 99173 |
|
2,613 |
2,142 |
$1K |
| 87807 |
|
67 |
52 |
$892.76 |
| 90715 |
|
910 |
747 |
$776.93 |
| 0124A |
|
26 |
13 |
$755.00 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
314 |
278 |
$565.42 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
689 |
581 |
$440.40 |
| 82947 |
|
101 |
75 |
$398.67 |
| 87076 |
|
75 |
58 |
$390.26 |
| 96127 |
|
89 |
74 |
$304.72 |
| 83655 |
|
173 |
145 |
$211.07 |
| 82950 |
|
31 |
29 |
$161.79 |
| 90619 |
|
321 |
319 |
$160.02 |
| 86592 |
|
1,665 |
1,329 |
$139.08 |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
310 |
268 |
$129.19 |
| 80061 |
Lipid panel |
228 |
214 |
$125.25 |
| 86803 |
|
111 |
83 |
$59.63 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
524 |
453 |
$55.69 |
| 86593 |
|
710 |
605 |
$33.00 |
| 94760 |
|
320 |
231 |
$6.26 |
| 36416 |
|
1,182 |
985 |
$3.76 |
| 86900 |
|
360 |
321 |
$3.00 |
| 91300 |
|
5,302 |
4,204 |
$0.02 |
| Q0144 |
Azithromycin dihydrate, oral, capsules/powder, 1 gram |
28 |
26 |
$0.02 |
| 99000 |
|
4,419 |
3,580 |
$0.00 |
| 91307 |
|
580 |
413 |
$0.00 |
| 90723 |
|
1,232 |
998 |
$0.00 |
| 86762 |
|
346 |
309 |
$0.00 |
| 90647 |
|
1,105 |
888 |
$0.00 |
| 92558 |
|
927 |
833 |
$0.00 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
122 |
110 |
$0.00 |
| 84443 |
Thyroid stimulating hormone (TSH) |
93 |
83 |
$0.00 |
| 87340 |
|
343 |
306 |
$0.00 |
| 80053 |
Comprehensive metabolic panel |
151 |
119 |
$0.00 |
| 90656 |
|
108 |
103 |
$0.00 |
| J3490 |
Unclassified drugs |
64 |
51 |
$0.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
194 |
155 |
$0.00 |
| 91301 |
|
340 |
301 |
$0.00 |
| 90677 |
|
106 |
100 |
$0.00 |
| 91306 |
|
107 |
94 |
$0.00 |
| 90680 |
|
16 |
13 |
$0.00 |
| 0500F |
|
27 |
26 |
$0.00 |
| 90696 |
|
16 |
15 |
$0.00 |
| 90670 |
|
1,492 |
1,177 |
$0.00 |
| G0452 |
Molecular pathology procedure; physician interpretation and report |
15 |
14 |
$0.00 |
| 90633 |
|
844 |
720 |
$0.00 |
| 90681 |
|
173 |
131 |
$0.00 |
| 83020 |
|
358 |
321 |
$0.00 |
| 90710 |
|
235 |
217 |
$0.00 |
| 86787 |
|
321 |
287 |
$0.00 |
| 99177 |
|
357 |
332 |
$0.00 |
| 81220 |
CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants |
135 |
123 |
$0.00 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
58 |
55 |
$0.00 |
| 84439 |
|
76 |
64 |
$0.00 |
| 90672 |
|
88 |
76 |
$0.00 |
| 90707 |
|
12 |
12 |
$0.00 |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
116 |
101 |
$0.00 |
| 90700 |
|
18 |
13 |
$0.00 |
| 91312 |
|
25 |
12 |
$0.00 |
| 90685 |
|
39 |
36 |
$0.00 |